Please provide your email address to receive an email when new articles are posted on . Mirum Pharmaceuticals received first treatment approval for treatment of cerebrotendinous xanthomatosis. Ctexli ...

Lipid metabolism and storage mechanisms underpin essential cellular processes, ensuring energy homeostasis and membrane integrity. At the cellular level, lipids are synthesised and stored ...

The FDA on Friday approved chenodiol (Ctexli) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Chenodiol -- a naturally occurring human bile acid also known as chenodeoxycholic ...

In addition to providing energy, lipids are also essential building blocks of our cell membranes. However, despite their ...

Chanarin-Dorfman syndrome (CDS) is a rare autosomal recessive disorder manifesting predominantly as congenital ichthyosiform erythroderma and systemic accumulation of neutral lipids. Mutations in the ...

The Food and Drug Administration approved Mirum Pharmaceuticals' Ctexli to treat Cerebrotendinous Xanthoma, a very rare lipid-storage disease. The approval makes Ctexli, or chenodiol, the first ...

Chanarin-Dorfman syndrome (CDS) is a rare, multisystemic, neutral lipid storage disease (NLSD) where the triglyceride accumulates in the leukocytes and other organs. Image Credit: ...

When microglia wind up with a belly full of lipid droplets, it’s a sign that the cells are rallying, perhaps in vain, to a neurodegenerative threat. But according to a study published July 10 in Cell ...

Cholesteryl Ester Storage Disease (CESD) is a rare autosomal recessive multisystem condition that belongs to the lysosomal storage disorders family. The liver is one of the most common sites of ...

SILVER SPRING, Md., Feb. 21, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.